• Debiopharm Group, of Lausanne, Switzerland, treated its first patient in an open-label, Phase III trial of triptorelin pamoate 22.5 mg 6-month formulation in children with central precocious puberty. The study will enroll 44 children from the U.S., Chile and Mexico, with a primary objective of evaluating safety and efficacy in reducing luteinizing hormone to prepubertal levels after six months.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST